ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT02660580

Public ClinicalTrials.gov record NCT02660580. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study identification

NCT ID
NCT02660580
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Enrollment
443 participants

Conditions and interventions

Interventions

  • Humira® Drug
  • MSB11022 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 15, 2016
Primary completion
Dec 30, 2016
Completion
Dec 17, 2017
Last update posted
Dec 26, 2023

2016 – 2017

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
San Luis Dermatology & Laser Clinic, Inc. San Luis Obispo California 93405
Florida Academic Centers Research and Education Coral Gables Florida 33134
Palm Beach Research Center West Palm Beach Florida 33409
Dermatology Treatment and Research Center Dallas Texas 75230
Modern Research Associates Dallas Texas 75231-5945
Dermatology Clinical Research Center of San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02660580, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 26, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02660580 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →